nodes	percent_of_prediction	percent_of_DWPC	metapath
Carbinoxamine—HRH1—Histamine receptors—HRH3—attention deficit hyperactivity disorder	0.0918	0.154	CbGpPWpGaD
Carbinoxamine—Captodiame—DRD3—attention deficit hyperactivity disorder	0.0761	0.189	CrCbGaD
Carbinoxamine—Chlorpromazine—DRD5—attention deficit hyperactivity disorder	0.04	0.0995	CrCbGaD
Carbinoxamine—Chlorphenamine—SLC6A3—attention deficit hyperactivity disorder	0.0319	0.0792	CrCbGaD
Carbinoxamine—Chlorprothixene—DRD3—attention deficit hyperactivity disorder	0.0256	0.0637	CrCbGaD
Carbinoxamine—Chlorprothixene—DRD1—attention deficit hyperactivity disorder	0.0252	0.0625	CrCbGaD
Carbinoxamine—HRH1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.025	0.0418	CbGpPWpGaD
Carbinoxamine—HRH1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0245	0.041	CbGpPWpGaD
Carbinoxamine—Chlorphenamine—SLC6A4—attention deficit hyperactivity disorder	0.0239	0.0593	CrCbGaD
Carbinoxamine—Clomipramine—ADRA2A—attention deficit hyperactivity disorder	0.0235	0.0583	CrCbGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.021	0.0351	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0206	0.0344	CbGpPWpGaD
Carbinoxamine—Chlorpromazine—DRD4—attention deficit hyperactivity disorder	0.0205	0.0509	CrCbGaD
Carbinoxamine—Clomipramine—SLC6A4—attention deficit hyperactivity disorder	0.0179	0.0445	CrCbGaD
Carbinoxamine—Chlorprothixene—DRD2—attention deficit hyperactivity disorder	0.0177	0.0441	CrCbGaD
Carbinoxamine—Chlorpromazine—DRD3—attention deficit hyperactivity disorder	0.0177	0.0439	CrCbGaD
Carbinoxamine—Chlorpromazine—DRD1—attention deficit hyperactivity disorder	0.0173	0.0431	CrCbGaD
Carbinoxamine—Chlorpromazine—ADRA2A—attention deficit hyperactivity disorder	0.0161	0.04	CrCbGaD
Carbinoxamine—HRH1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0148	0.0248	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0143	0.0239	CbGpPWpGaD
Carbinoxamine—HRH1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0138	0.0231	CbGpPWpGaD
Carbinoxamine—Clomipramine—HTR2A—attention deficit hyperactivity disorder	0.0138	0.0342	CrCbGaD
Carbinoxamine—Chlorprothixene—HTR2A—attention deficit hyperactivity disorder	0.0137	0.0341	CrCbGaD
Carbinoxamine—HRH1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0134	0.0223	CbGpPWpGaD
Carbinoxamine—HRH1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0131	0.022	CbGpPWpGaD
Carbinoxamine—HRH1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.013	0.0217	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0125	0.0209	CbGpPWpGaD
Carbinoxamine—Chlorpromazine—DRD2—attention deficit hyperactivity disorder	0.0122	0.0304	CrCbGaD
Carbinoxamine—HRH1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0121	0.0202	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.0116	0.0194	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0112	0.0188	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.011	0.0185	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0109	0.0182	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0101	0.017	CbGpPWpGaD
Carbinoxamine—Chlorpromazine—HTR2A—attention deficit hyperactivity disorder	0.00944	0.0235	CrCbGaD
Carbinoxamine—HRH1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.00846	0.0142	CbGpPWpGaD
Carbinoxamine—CYP2C19—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00743	0.0124	CbGpPWpGaD
Carbinoxamine—HRH1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.00711	0.0119	CbGpPWpGaD
Carbinoxamine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.00683	0.0114	CbGpPWpGaD
Carbinoxamine—CYP3A4—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.00659	0.011	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00482	0.00807	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00472	0.0079	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00469	0.00785	CbGpPWpGaD
Carbinoxamine—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00446	0.00746	CbGpPWpGaD
Carbinoxamine—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00436	0.0073	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00413	0.00691	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00405	0.00677	CbGpPWpGaD
Carbinoxamine—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00377	0.00631	CbGpPWpGaD
Carbinoxamine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00337	0.00564	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00327	0.00548	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00315	0.00526	CbGpPWpGaD
Carbinoxamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.0031	0.00518	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00308	0.00516	CbGpPWpGaD
Carbinoxamine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00307	0.00514	CbGpPWpGaD
Carbinoxamine—HRH1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00302	0.00506	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00286	0.00479	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.0028	0.00469	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00266	0.00445	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00265	0.00444	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00258	0.00431	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00253	0.00424	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.0025	0.00419	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00245	0.0041	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00241	0.00403	CbGpPWpGaD
Carbinoxamine—CYP2B6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00238	0.00399	CbGpPWpGaD
Carbinoxamine—CYP2B6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00237	0.00396	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00235	0.00393	CbGpPWpGaD
Carbinoxamine—CYP2E1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00233	0.00391	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00233	0.0039	CbGpPWpGaD
Carbinoxamine—CYP2E1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00232	0.00388	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.0023	0.00385	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00228	0.00381	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00221	0.00369	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00217	0.00363	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00214	0.00359	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00214	0.00357	CbGpPWpGaD
Carbinoxamine—HRH1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00211	0.00353	CbGpPWpGaD
Carbinoxamine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00202	0.00339	CbGpPWpGaD
Carbinoxamine—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00202	0.00338	CbGpPWpGaD
Carbinoxamine—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.002	0.00335	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.002	0.00334	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00199	0.00333	CbGpPWpGaD
Carbinoxamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00189	0.00316	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00187	0.00312	CbGpPWpGaD
Carbinoxamine—CYP2C19—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.0018	0.00301	CbGpPWpGaD
Carbinoxamine—CYP2C19—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00179	0.00299	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00178	0.00297	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00178	0.00297	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00174	0.00291	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00174	0.0029	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00168	0.00281	CbGpPWpGaD
Carbinoxamine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00166	0.00277	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00165	0.00277	CbGpPWpGaD
Carbinoxamine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00165	0.00275	CbGpPWpGaD
Carbinoxamine—CYP2C9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00164	0.00275	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00163	0.00273	CbGpPWpGaD
Carbinoxamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00163	0.00273	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00163	0.00273	CbGpPWpGaD
Carbinoxamine—CYP2C9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00163	0.00273	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00162	0.00271	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00161	0.0027	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00158	0.00265	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00152	0.00254	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00142	0.00238	CbGpPWpGaD
Carbinoxamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.0014	0.00234	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00121	0.00202	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00111	0.00186	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0011	0.00183	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00108	0.00181	CbGpPWpGaD
Carbinoxamine—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00108	0.0018	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00107	0.00179	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00106	0.00178	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00106	0.00177	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.000981	0.00164	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000975	0.00163	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000958	0.0016	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000955	0.0016	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000954	0.0016	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00095	0.00159	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000934	0.00156	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.000934	0.00156	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.000922	0.00154	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.000916	0.00153	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000891	0.00149	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000863	0.00144	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000859	0.00144	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000848	0.00142	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000837	0.0014	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000825	0.00138	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00078	0.00131	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000737	0.00123	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000677	0.00113	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000673	0.00113	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000673	0.00113	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000672	0.00112	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000662	0.00111	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000659	0.0011	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000659	0.0011	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000648	0.00109	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000648	0.00108	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000615	0.00103	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000603	0.00101	CbGpPWpGaD
Carbinoxamine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000602	0.00101	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00057	0.000953	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00057	0.000953	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000566	0.000947	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00056	0.000938	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000546	0.000914	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000538	0.0009	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000527	0.000882	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000526	0.000881	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000521	0.000872	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000512	0.000857	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00051	0.000853	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000508	0.000851	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000508	0.000851	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000502	0.000839	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000501	0.000838	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—DPYD—attention deficit hyperactivity disorder	0.0005	0.000837	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000495	0.000828	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000468	0.000783	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000468	0.000783	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000465	0.000778	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000464	0.000776	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000464	0.000776	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000461	0.000771	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00046	0.00077	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000456	0.000763	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000455	0.000762	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000443	0.000741	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000434	0.000726	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000428	0.000716	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000424	0.00071	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000408	0.000682	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000406	0.00068	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000405	0.000677	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000399	0.000668	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000396	0.000664	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000387	0.000648	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000374	0.000626	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000371	0.00062	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000356	0.000596	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000353	0.00059	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	0.000345	0.000578	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000343	0.000574	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000332	0.000556	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000323	0.00054	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—COMT—attention deficit hyperactivity disorder	0.000308	0.000516	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000306	0.000512	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000306	0.000512	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000306	0.000512	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000301	0.000503	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000297	0.000496	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000283	0.000474	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000281	0.000471	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000281	0.00047	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00028	0.000468	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000279	0.000467	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.00027	0.000453	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000244	0.000409	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000233	0.000389	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	0.000185	0.00031	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000184	0.000308	CbGpPWpGaD
Carbinoxamine—CYP2B6—Metabolism—EP300—attention deficit hyperactivity disorder	0.000175	0.000293	CbGpPWpGaD
Carbinoxamine—CYP2E1—Metabolism—EP300—attention deficit hyperactivity disorder	0.000171	0.000287	CbGpPWpGaD
Carbinoxamine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000171	0.000286	CbGpPWpGaD
Carbinoxamine—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	0.000148	0.000248	CbGpPWpGaD
Carbinoxamine—CYP2C19—Metabolism—EP300—attention deficit hyperactivity disorder	0.000132	0.000221	CbGpPWpGaD
Carbinoxamine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	0.000121	0.000203	CbGpPWpGaD
Carbinoxamine—CYP2C9—Metabolism—EP300—attention deficit hyperactivity disorder	0.00012	0.000202	CbGpPWpGaD
Carbinoxamine—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	7.94e-05	0.000133	CbGpPWpGaD
